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Objectives:
* Major:
- To study the association of increased homocysteine and Coronary 
Atherosclerosis among Palestinian patients in Palestine.
* Minor:
- To correlate between Severity of Atherosclerosis and Homocysteine 
Concentration.
- To compare Homocysteine as a Risk Factor for Coronary 
Atherosclerosis and Other Conventional Risk Factors.
:صخلم
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 العديد من الباحثين ,والعلماء أثبت أن ارتففاع نسفبة الهوموسيسفتين الكلفي ففي
 البلزما لديه ارتباط قوي مع أمراض الشرايين التاجية، المراض القلبية الوعائيففة،
وأمراض القلب الخرى.
 في هذه الدراسة تم البحث في امكانية وجود علقفة قويفة بيفن الهوموسيسفتين
  (. وتم أيضا دراسة العلقة بين00.0=Pوأمراض الشرايين التاجية في فلسطين) 
 الهوموسيستين الكلي وحدة الصابة بتصلب الشرايين التاجية. وبالضافة لذلك تم
 أيضففا قيففاس مسففتويات الكوليسففترول، الففدهنيات الثلثيففة، حففامض اليوريففك،
 والكوليسترول عالي الكثافة ومنخفض الكثافة لدراسفتها كعوامفل خطفر تقليديفة
لمراض القلب ومقارنتها مع الهوموسيستين.
-12الشخاص في هذه الدراسة تفم تجنيفدهم مفن الفذكور والنفاث بعمفر مفن 
 سنة والذين خضعوا لعمليات القسطرة القلبية في الفترة مفن شفهر اذار الفى58
  في قسم القسطرة ففي مستشففى رام اف الحكفومي4002شهر اب من عام 
في رام ا بفلسطين.
  شفخص مفوزعين علفى883عدد الشخاص الذين شفاركوا ففي هفذه الدراسفة 
النحو التالي:
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  شفخص: وهفؤلء هفم الفذين981الحفالت المرضفية وعفددهم (1
 % في05 ≤خضعوا لعملية القسطرة وتم تشخيصهم بوجود انسداد بنسبة  
أي من الشرايين التاجية.
  اشخاص وهفم هفؤلء301المجموعة الضابطة السلبية وعددهم (2
 الذين خضعوا لعمليفات القسفطرة وكفانت نتيجفة القسفطرة وجفود انسفداد
% في اي من الشراين التاجية او عدم وجود اي انسداد.05بنسبة > 
  شخص وهم عبارة عفن مجموعفة69والمجموعة الثالثة وعددها (3
 ضابطة عشوائية تم اختيارها من السكان العاديين بشرط خلفوهم مفن اي
من امراض القلب وعدم تعاطيهم اي ادوية لها علقة بأمراض القلب.
 شففوهد فففي هففذه الدراسففة ان الحففالت المرضففية لففديها ارتفففاع فففي معففدل
  (،00.0=P% مقارنة بالمجموعة الضابطة السلبية ) 2.13الهوموسيستين بمقدار 
 ولكن بين المجموعتين الضابضطتين لم يكن هناك أي فرق احصائي بينهفم ففي
 (.741.0=Pمعدل الهوموسيستسن ) 
 النسبة الثنائية بين تصلب الشرايين التاجية وارتفاع نسبة الهوموسيستين في الفدم
 ( وذلك قبل تعديل العمفر والجنفس وبقيفة99.4-41.2  ،IC% 59  ) 72.3كانت 
 العوامفل المفؤثرة ففي نسفبة الهوموسيسفتين وذلفك باسفتخدام القيمفة الحديفة
31
  ميكرومول/ لتر) هذه القيمة تم تحديدها من هفذه5.4  ± 7.41للهوموسيستين 
 الدراسة وهي تساوي معدل الهيموسيستين لدى المجموعة الضابطة والنحفراف
 المعياري(، وبعد تعديل العمفر والجنفس وبقيفة العوامفل كفانت النسفبة الثنائيفة=
(.99.4 -59.1 ،IC% 59 )21.3
 بالضافة لذلك كان هناك علقة احصائية قوية بين حدة ودرجة تصفلب الشفرايين
 التاجية ) تم قياسها على أسفاس عفدد الشفرايين المغلقفة لفدى المريفض( وبيفن
 (.00.0=Pزيادة وارتفاع نسبة الهوموسيستين في الدم ) 
 أما بخصوص عوامل الخطفورة التقليديفة وخاصفة الكوليسفترول عفالي الكثاففة،
 الكوليسترول الحفر والفدهنيات الثلثيفة فلفم تظهفر هفذه الدراسفة وجفود علقفة
 احصفائية مفع تصفلب الشفرايين التاجيفة مقارنفة بالهوموسيسفتين وكفانت القيفم
الحصائية لها كما يلي على التوالي:
 ((  ،  بينما  لعوامل  الخطورة  الخرى  وخاصة705.0 =P ,770.0 =P ,383.0 =P 
 حامض اليوريك، والكوليسترول منخفض الكثاففة أظهفرت هفذه الدراسفة وجفود
 علقة احصائية قوية مع تصلب الشرايين التاجية وكانت قيمتها الحصائية كما يلي
,110.0 =Pعلى التوالي )
(.00.0 =P 
41
 في النتيجة النهائية أظهرت هذه الدراسة أن الهوموسيستين لديه علقة قوية مففع
 تصلب الشرايين التاجية وحدة الصابة بها. ولكن نتائج هذه الدراسفة علفى هفذه
 الفئة من المرضى في فلسطين يمكنها أن تفتح الطريق وتشجع الباحثين لعمففل
 دراسفات أشفمل وأعفم لدراسفة الهوموسيسفتين كأحفد عوامفل الصفابة بتصفلب
 الشرايين وأمراض القلب المختلففة وكأحفد عوامفل مراقبفة تطفور الصفابة بهفذه
المراض في فلسطين.
51
  
Abstract:
Many researchers have shown that elevated total plasma Homocysteine 
has a significant association with coronary heart diseases, cardiovascular 
diseases and other cardiac diseases.
In this present  case control  study, I  investigated whether fasting total 
Homocysteine  has  a  strong association  with coronary  artery diseases. 
Also, correlation between fasting t-Hcy and severity of atherosclerosis 
was  studied.  Furthermore,  levels  of  cholesterol,  triglycerides,  HDL, 
LDL,  and  uric  acid,  were  studied  as  conventional  risk  factors  of 
atherosclerosis to compare them with total Homocysteine. Subjects were 
recruited from men and women, aged 21 to 85 years, who underwent 
coronary angiography (cardiac catheterization) between March 2004 and 
August 2004 at Ramallah Hospital catheterization laboratory. Cases (n= 
16
189)  where  defined  as  those  with  ≥  50% occlusion  of  any  coronary 
artery,  while  control  subjects  (n=103)  had  <  50%  occlusion  in  any 
coronary artery or had no occlusion at all.  In addition a population - 
based control  group free from clinical  cardiovascular  disease (n= 96) 
was studied.
Cases  had  31.2  %  higher  mean  fasting  total  homocysteine  than  both 
control groups (P=0.00). While between the two control groups the mean 
total plasma homocysteine is almost the same, and there is no statistical 
difference  between  their  means  (P=0.147).  The  odds  ratios  (OR)  for 
coronary atherosclerosis and hyperhomocysteinemia was 3.27 (95% CI, 
2.14 – 4.99) using Hcy cutoff value 14.7 (Established cutoff value from 
this study) and before adjusting for age, sex and other confounders. But 
after adjusting for age, sex and other confounders OR was 3.12(95% CI, 
1.95  –  4.99).  Furthermore,  increasing  fasting  total  homocysteine  was 
associated  with  severity  of  atherosclerosis  measured  as  increasing 
number  of  occluded arteries  (P=0.00).  For the other  conventional  risk 
factors HDL, cholesterol, and triglycerides were statistically insignificant 
as  risk  factors  for  coronary  atherosclerosis  and their  significance  was 
17
(P=0.383,  P=0.077, and P=0.507 respectively). While for Uric acid and 
LDL  they  were  statistically  significant  (P=  0.011  and  P=  0.00 
respectively).
In conclusion, the main finding in this population group is that plasma 
total Homocysteine is strongly related to coronary atherosclerosis and to 
its severity. These results should encourage further studies of tHcy as a 
prognostic marker or risk factor for coronary atherosclerosis in Palestine.
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Chapter 1
 INTRODUCTION
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1.1 Introduction: 
Cardiovascular  diseases  remain  the  leading  causes  of  mortality  in 
developed countries. Many factors can contribute to the development of 
atherosclerosis, thrombosis, and subsequent vascular and coronary heart 
disease1.  An increase in plasma cholesterol,  smoking,  and obesity  are 
important risk factors in the development of the atherosclerotic process. 
Several  clinical  studies  support  the  link  between  increased  levels  of 
homocysteine and the development of cardiovascular, cerebrovascular, 
and  peripheral  vascular  disease,  and  thus  the  inclusion  of  plasma 
homocysteine level as a risk factor.2 
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Several  studies  have  reported  that  a  high  plasma  homocysteine 
concentration  is  a  risk  factor  for  vascular  diseases.  The  strongest 
evidence  comes  from cross-sectional  and  case-control  studies,  which 
generally support the association between a high plasma homocysteine 
concentration and a  risk of  CVD3,  4.  However,  data  from prospective 
cohort  studies  indicate  weaker  or  no  association  between  the  plasma 
homocysteine  concentration  and  the  risk  of  CVD  (Table  1).  Five 
prospective studies have reported that an elevated plasma homocysteine 
concentration increases the risk of CVD5,6,7,8,9, whereas an equal number 
of studies failed to show any association between plasma homocysteine 
and  CVD10,11,12,13,14  .Thus,  data  from prospective  studies  indicate  little 
predictive ability of plasma homocysteine in CVD.
The  theory  of  homocysteine  being  an  independent  risk  factor  for 
vascular diseases is supported by experimental evidence of mechanisms 
by which homocysteine might cause vascular damage and disease. The 
possible mechanisms include endothelial dysfunction and injury, which 
is followed by platelet activation and thrombus formation. Homocysteine 
can exert a direct cytotoxic effect on endothelial cells, which is related to 
21
generation of potent reactive oxygen species15, impaired production of 
endothelium-derived nitric  oxide and endothelial  dysfunction16,  17,  and 
stimulation of smooth-muscle cell proliferation18. It has been postulated 
that  homocysteine  promotes  atherosclerosis  by  increasing  lipid 
peroxidation and oxidation of LDL, but this has not been confirmed in 
all  studies19,  20.Another  suggested  mechanism  of  the  vascular  damage 
associated  with  homocysteine  relates  to  formation  of  oxygen  free 
radicals, which cause vascular damage, proliferation of smooth-muscle 
cells,  alteration  of  endothelial  function  and  structure,  and  increased 
thrombogenicity  that  leads  to  atherothrombosis21.  However,  an 
alternative  explanation  for  an  association  between  homocysteine  and 
vascular damage has been proposed22. It has been suggested that plasma 
homocysteine  concentration  increases  after  tissue  damage,  and  the 
elevated levels of homocysteine further promote the endothelial damage. 
A high plasma homocysteine level would thus be an indicator of tissue 
damage  and  a  promoter  or  enhancer  of  inflammatory  thickening  of 
vascular damage.22 Findings from a Finnish study support the possibility 
that  homocysteine  is  a  consequence  rather  than  a  cause  of  vascular 
22
damage and disease14.  In addition, some epidemiological  studies  have 
observed that low serum folate and B6 vitamin concentrations increase 
the risk for vascular diseases, and the elevated plasma tHcy would thus 
be a marker of the low vitamin concentrations13, 23, 24.  These findings are 
strengthened by a recent study showing that folic acid supplementation 
improves endothelial  function in patients with coronary artery disease 
independently of plasma tHcy reduction25.
Table (1): Major prospective studies on plasma tHcy concentration and 
CVD26.
Study 
(Reference(
Follow-
up 
(years(
Out- 
come
Study 
population
Cases  / 
controls
Sex Age Plasma 
tHcy 
cases / 
others 
(µmol/l(
Adjusted relative 
risk (95% CI(
Physicians’ Health 
Study (Stampfer et 
al. 1992(
5 MI, CHD 
death
14916 271/  
271
M 40–84 11.1 / 10.5 3.4) 1.3–8.8 (a
North Karelia 
Study(Alfthan et al. 
1994(
9 MI, 
stroke
7424 265/  
265
M, F 40–64 10.0 / 9.8) 
M(
1.06) 0.64–1.77 (b
Tromso Study 
(Arnesen et al. 
1995(
3.5 CHD 21826 122/  
478
M, F 12–61 12.7 / 11.3 1.32) 1.05–1.65 (c
Physicians’ Health 
Study (Chasan-
Taber et al. 1996(
7.5 MI 14916 333/  
333
M 40–84 not 
reported
1.7) 0.9–3.3 (a
Multiple Risk Factor 
Intervention Trial 
(MRFIT) (Evans et 
al. 1997(
>11 MI 12866 93 / 186 M 35–57 12.6 / 13.1 0.82) 0.55–1.54 (d
>11 CHD 
death
 147/  
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  12.8 / 12.7  
Atherosclerosis 
Risk is 
Communities 
3.3 CHD 15792 232/  
527
M, F 45–64 8.9 / 8.5 1.28) 0.5–3.2 (e
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(ARIC) (Folsom et 
al. 1998(
British United 
Provident 
Association Study 
(BUPA) (Wald et al. 
1998(
8.7 Fatal 
CHD
21250 229/  
1126
M 35–64 13.1 / 11.8 2.9) 2.04–4.12 (d
Framingham Study 
(Bostom et al. 
1999(
10 CVD 
mortality 
1933 244 
cases
M, F 59–91 not 
reported
1.52) 1.16–1.98 (f
Women’s Health 
Study (Ridker et al. 
1999(
3 CVD 28263 122/  
244
F postm
enop.
14.1 / 12.4 2.3) 1.2–4.3 (d
Finnish Mobile 
Clinic Health 
Examination Survey 
(Knekt et al. 2001(
13 MI, CHD 
death
3471 272/  
524
M 45–64 10.8 / 11.2 0.90) 0.51–1.60 (e
MI, myocardial infarction; CHD, coronary heart disease; IHD, ischaemic heart diseasea top 5 % compared with lowest 10 % of total 
homocysteine levels, b highest 10 % compared with lower 90 % of total homocysteine levels, c per 4 µmol/l increase in total 
homocysteine level, d highest compared with lowest quartiles of total homocysteine levels, e highest compared with lowest quintile 
of total homocysteine levels, f highest compared with three lower quartiles of total homocysteine levels
Unlike  some  independent  risk  factors  of  cardiovascular  disease,  i.e., 
lipoprotein (a), plasma homocysteine levels can often be therapeutically 
altered  by  vitamin  supplementation.  Consequently,  several  trials  are 
underway in the United States and Europe26  are conducted to prove that 
reducing  plasma  total  homocysteine  will  reduce  the  risk  of 
atherosclerosis; these ongoing trials are mentioned in Table (2).
Table  (2):  Ongoing  clinical  trials  of  Homocysteine-lowering  vitamin 
therapy26.
Study Sample 
Size
Folic acid 
(mg)
Vitamin Intervention for Stroke Prevention(VISP),USA 3600 2.5 vs 0.2
The  Women’s  Antioxidant  Cardiovascular 
Study(WACS), USA
6000-8000 2.5
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The Study of Effectiveness of Additional Reduction in 
Cholesterol and Homocysteine(SEARCH), UK
12000 2
Cambridge Heart Antioxidant Study(CHAOS), UK 4000 5
Norwegian  Vitamin  Interventional  Trail(NORVIT), 
Norway
3000 0.8
Western-Norway  B-Vitamin  Intervention  Trial 
(WENBIT), Norway
2000 0.8
The Prevention with a Combined Inhibitor and Folate in 
Coronary Heart Disease( PACIFIC), Australia
10000 2
Heart Outcome Prevention Evaluation-2(HOPE-2) 5000 2.5
All these ongoing trials concentrate on homocysteine-lowering vitamin 
therapy. Most of them did not issue their results till now. But, the most 
common  target  for  all  of  them  is  to  reduce  risk  of  coronary 
atherosclerosis,  CAD,  CVD,  and  stroke  by  lowering  homocysteine 
through vitamin therapy.
Epidemiological studies have shown that too much homocysteine in the 
blood is related to a higher risk of coronary heart disease,  stroke and 
peripheral  vascular  disease.  Those  epidemiological  studies  are  listed 
chronologically as follow: 
• 1993-  Prospective  studies  demonstrating  that  tHcy  within  the 
normal range is related to myocardial infarction and to stroke 6, 27. 
• 1994- Demonstrating that children of vegan mothers had elevated 
Methylmaonic acid and tHcy levels consistent with a functional vitamin 
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B12 deficiency, predisposing to neurological damage in infancy and even 
in adolescence28, 29. 
• 1995-  Demonstrating  that  several  life-style  factors  such  as 
smoking,  coffee drinking, intake of fruits and vegetables and physical 
activity are among the important  determinants of tHcy (the Hordaland 
Homocysteine Study) 30. 
• 1996-  Showing  that  markedly  elevated  tHcy  (>40  µM)  in  the 
general  population  is  usually  due  to  a  combination  of  a  genetic 
disposition  (MTHFR  677C->T  mutation)  and  life-style  factors 
predisposing  to  high  tHcy  levels.  The  majority  of  these  individuals 
obtained  a  normal  tHcy  level  by  increasing  their  folate  intake  (the 
Hordaland Homocysteine Study) 31. 
• 1996-  tHcy  in  children  was  found  to  be  associated  with 
cardiovascular  mortality  of  their  male  relatives,  suggesting  a  strong 
genetic predisposition of high tHcy levels 32. 
• 1997-  Results  from  the  European  concerted  action  (COMAC) 
project "Homocysteine and Vascular Disease", demonstrated for the first 
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time that tHcy strongly interacts with established risk factors for vascular 
disease, especially hypertension and smoking 33. 
• 1997- tHcy was reported to be a strong predictor of mortality in 
patients with confirmed coronary artery disease. The mortality risk within 
5 years was 25 % in patients with tHcy >20 µM, vs 4 % in patients with 
tHcy <9 µM. The finding was published in the NEJM 34. 
• 1997- Finding that  the inborn error homocysteinuria is  probably 
much more common (>1/20,000) than previously anticipated (1/300,000). 
Moreover,  in  Norway,  homocysteinuria  is  most  often  related  to  one 
particular 'Norwegian mutation'.  Patients with this mutation respond to 
treatment with pyridoxine 35. This finding motivates new-born screening 
for homocysteinuria in Norway (pilot study starting in 1998/99). 
• 1998- The first report on a substantial increase in tHcy in subjects 
consuming large amount of filtered coffee 34. 
• 2000- Reporting that plasma tHcy was associated with pregnancy 
complications  and  adverse  outcomes  in  the  large  Hordaland 
homocysteine cohort 36. 
27
• 2001-Reporting  that  Plasma  tHcy  is  a  strong  predictor  of  both 
cardiovascular and noncardiovascular mortality in a general population of 
65–72-y-olds 36. 
• 2003-  Reporting  that  hyperhomocysteinemia  and  the  MTHFR 
677TT  genotype  are  related  to  depression  in  6000  subjects  from the 
Hordaland homocysteine cohort 37. 
• 2004-  Demonstration  that  changes  in  lifestyle  has  a  modest 
(compared to folate supplementation) but significant  effect  on tHcy in 
7000 subjects over 6 years period 38. 
• 2004- 
The largest study to date (2168 case-control pairs) on the MTHFR 677C-
>T polymorphism and (colorectal ) cancer, demonstrating reduced risk of 
27% and  35%,  respectively,  of  colorectal  cancer  in  subjects  with  the 
MTHFR 677 TT and MTR 2756 GG genotypes 39. 
Two reports have strengthened the evidence for this relationship:
1.  A  large  multi-center  European  trial,  published  in  the  issue  of  the 
Journal of the American Medical  Association,  found that among men 
and women younger than age 60, the overall risk of coronary and other 
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vascular  disease  was  2.2  times  higher  in  those  with  plasma  total 
homocysteine levels in the top fifth of the normal range compared with 
those in the bottom four-fifths4. The risk was independent of other risk 
factors, but was notably higher in smokers and persons with high blood 
pressure.33
2.  A  Norwegian  study,  published  in  the  issue  of  the  New  England 
Journal  of  Medicine34,  found  that  among  587  patients  with  coronary 
heart disease, the risk of death after four to five years was proportional 
to plasma total homocysteine levels. The risk rose from 3.8% in those 
with the lowest levels (below 9umol/L) to 24.7% with the highest levels 
(greater than 15 umol/L). Further, in this study Nygard et.al.34 found that 
approximately 4% of patients with homocysteine levels below 9 umol/L 
died after 4 years, compared with about one quarter of subjects whose 
levels were 15umol/L or higher.  Elevated homocysteine in this group 
was strongly related to MI, even after adjusting for confounding factors. 
These  investigators  calculated an adjusted mortality  ratio of  1.6:1 for 
patients with total homocysteine levels of 15umol/L34.
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Also,  pioneering  clinical  studies  in  patients  with  CAD  were 
performed  by Wilcken  and Wilcken in  Australia40.  Those  researchers 
found that patients younger than 50 years of age with CAD had elevated 
homocysteine  levels  compared  with  normal  subjects.  The  Norwegian 
Tromoso Heart Study showed a 40% increased risk of MI with each 4 
umol/L increase in homocysteine levels41.
In  the  United  States,  a  sub  study  of  the  Physicians'  Health  Study5,11 
yielded  results  consistent  with  the  findings  of  the  Norwegian  study. 
A  meta-analysis  of  studies  of  patients  with  coronary  heart  disease 
demonstrated  a  similar  increase  in  risk  for  each 5umol/L  increase  in 
homocysteine42,43.  Research  in  this  field,  however,  has  not  produced 
uniform results. For example, the Multiple Risk Factor Intervention Trial 
failed  to  show a link between elevated  homocysteine  and CAD.  The 
populations under investigation and their nutritional status, the samples 
and  tests  used  to  measure  homocysteine,  and  even  the  sample  sizes, 
might explain discrepancies among studies3,42. The weight of evidence, 
however, still supports homocysteine as a vascular risk factor44.
1.2 Review of Homocysteine Metabolism
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1.2.1 Background:
In the late 1960's Dr. Kilmer McCully, a Harvard Professor, had 
been reviewing cases of the rare condition - homocysteinuria in children. 
He  noted  that  all  of  the  cases  showed  marked  development  of 
atherosclerotic  plaques.  From  this  observation,  he  postulated  that 
elevation of blood homocysteine caused arterial lesions by a direct effect 
on the cells and tissues of the arteries45, 46. 
Homocysteine  is  a  naturally  occurring,  sulfur-containing 
amino  acid  formed  from the  metabolism  of  methionine,  an  essential 
amino acid, derived from the diet. Sources of methionine include meats 
and  fish  (highest  content),  vegetables,  fruits,  nuts,  and  cereal  grains. 
Methionine  is  the  only  known  source  of  homocysteine.  Normally, 
homocysteine is rapidly metabolized to prevent its concentration from 
increasing in the circulation47,48. 
Homocysteine  metabolism  is  controlled  by  one  of  two 
biochemical pathways: Transsulfuration and remethylation (Fig 1)49 
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Fig 1. Methionoine cycle and homocysteine metabolism. 
In conditions in which methionine is in excess or cysteine synthesis is 
required, homocysteine enters the transsulfuration pathway. The reaction 
is  catalyzed  by  the  enzyme  cystathionine  B-synthase,  the  activity  of 
which depends on the cofactor vitamin B6. During periods of methionine 
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deficiency,  homocysteine  enters  the  remethylation  pathway.  In  most 
tissues,  remethylation  occurs  via  the  folate  cycle,  using  the  enzymes 
N5N10-methylene-tetrahydrofolate reductase (MTHFR) and methionine 
synthase (MS); methylated folate serves as the methyl donor49.
An  alternative  pathway  occurs  primarily  in  the  liver  via  the 
enzyme  betaine-homocysteine  methyl-transferase;  this  pathway  is 
independent of vitamin B12 and folate, and the cofactor betaine donates 
the methyl group49. 
The intracellular levels of homocysteine are kept within a narrow range. 
Increase of 1 level of intracellular homocysteine caused by augmented 
production  or  a  reduction  in  its  metabolism  results  in  corresponding 
increases in blood levels.  These changes therefore reflect  intracellular 
homeostasis of those pathways involved with homocysteine metabolism. 
Although plasma concentrations of homocysteine have low short-term 
and long-term, within-individual variation, high methionine, low folate, 
or low cobalamin (vitamin B12) levels, as well as agents that interfere 
with  homocysteine  metabolism,  cause  an  increase  in  homocysteine 
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export  from  cells,  thus  increasing  the  concentration  of  plasma 
homocysteine50.
Human  plasma  contains  both  the  reduced  and  oxidized  species  of 
homocysteine.  The  reduced  or  sulfhydryl  (-SH)  form  is  called 
homocysteine;  the  oxidized  or  disulfide  (-S-S-)  form is  composed  of 
homocysteine and mixed disulfides (Fig 2)51.
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Reduced                             NH3+ 
Homocysteine
                                      -OOCCH2CH2-SH                   1%
 
                                              NH3+
Oxidized                                
                                -OOCCH2CH2 S                    5 - 10%
                                       
                                       -OOCCHCH2 -S
                                                 NH3+
Mixed Disulfides             
Protein - Bound                    NH3+
Homocysteine 
                                -OOCCH2CH2      S                 80 - 90%
                                       
                                             Protein         S
Cysteine-Homocysteine    
                                                 NH3+
                                -OOCCH2CH2- S                   5 - 10%
                                       
                                       -OOCCHCH2    S
                                            
                                                 NH3+
Fig 2: Constituents of total homocysteine and percentage of each in 
plasma.
The mixed disulfides of plasma homocysteine occur by binding 
with  other  thiols,  i.e.,  compounds  containing  —SH groups;  they  are 
primarily  homocysteine-cysteine  residues  or  proteins  that  contain 
reactive cysteine groups that form protein-bound homocysteine. 
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Albumin  binds  approximately  70%  to  80%  of  the  plasma 
homocysteine; it is the major binding protein for thiols in human plasma. 
Most (98%-99%) of the plasma homocysteine is in the oxidized form, 
i.e.,  protein-bound  and  "free."  Healthy  individuals  have  free 
homocysteine (reduced and mixed disulfides) levels of approximately 2 
to 3 (umol/L or 20% to 30% of the total." Only a trace amount (<0.3 
umol/L) of free reduced homocysteine can be detected in plasma. Total 
homocysteine  is  the  total  of  all  forms  of  homocysteine  that  exist  in 
plasma or serum51. 
Homocysteine  is  reabsorbed  from the  glomerular  ultra  filtrate  by  the 
renal  tubule  cells.  Its  clearance  rate  is  approximately  1% of  that  of 
creatinine.  Thus  only  a  small  portion  of  homocysteine  is  normally 
excreted through the kidneys. Because renal tubular cells can metabolize 
homocysteine,  impairment  of  tubular  cell  function  depresses  the 
intracellular  catabolism  of  homocysteine,  thereby  elevating  levels  of 
plasma homocysteine51. 
Patients  who  are  folate  -  or  cobalamin-deficient  have  normal  total 
homocysteine clearance from plasma, which suggests that their elevated 
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total homocysteine level is due to increased homocysteine export from 
tissues  into  plasma compartment.  Hyperhomocysteinemia  observed in 
renal  failure  appears  to  be  due  to  the  marked  reduction  in  total 
homocysteine clearance; this suggests that the kidney play an important 
role in the elimination of homocysteine from the plasma. Table (3) lists 
the fasting levels of total plasma homocysteine in healthy individuals 
and patients with hyperhomocysteinemia51.
Table (3). Clinical Ranges for Homocysteine in plasma (Fasting) 51
Clinical Condition Range (umol/L(
Healthy 5-15 ( desirable > 10 )
Hyperhomocysteinemia
                        Moderate 15 – 30
                       Intermediate 30 – 100
                        Severe <  100
1.2.2 Factors Affecting Homocysteine Level:
Because  homocysteine  metabolism  is  complex  involving  several 
enzymatic reactions and cofactors (i.e., vitamin B6, vitamin B12, folic 
acid) any inhibition of its metabolism or depletion of cofactors can lead 
to  hyperhomocysteinemia  and homocysteinuria52.  A variety  of  factors 
are known to affect plasma levels of homocysteine, including enzyme 
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deficiencies (genetic disorders), liver and renal disease, hypothyroidism, 
pharmacological agents, age, and possibly gender53. Although males tend 
to have slightly higher levels than females, a recent study suggests that 
gender does not significantly influence homocysteine levels. Conditions 
associated with elevated levels of homocysteine are listed in Table (4)33, 
51.
Table 4. Conditions Associated With Elevated Plasma Homocysteine51 
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Genetic factors 
    Cystathionine B- synthase deficiency.
    Methionine synthase deficiency ( Cobalamin C disease )  
    Methylene tetrahydrofolate reductase deficiency ( congenital  deficiency )
  Methylene tetrahydrofolate reductase variant (decreased enzyme activity).   
Demographic factors 
   Ethnic origin 
   Increased age 
   Male (?) 
   Postmenopausal 
Acquired factors 
   Deficiencies in folate, vitamin B6, vitamin B12 
   Health conditions :
      End-stage renal disease    
      Impaired renal function 
      Post organ transplantation.
      Hypothyroidism 
      Malignant diseases 
      Hypertension 
      Therapeutic drugs 
Lifestyle factors 
   Chronic alcohol consumption 
   Chronic illicit substance use 
   Excessive coffee consumption 
   Lack of exercise 
   Smoking 
Preanalytical variables 
   Delay in separating plasma from cells 
   Nonfasting sample 
1.3 Genetic Disorders of Metabolism:
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Genetic  defects  leading  to  deficiencies  in  the  enzymes  involved  in 
homocysteine  metabolism  result  in  marked  elevations  in  the 
concentration  of  homocysteine  in  plasma  and  in  urine.  The  most 
common genetic cause of severe hyperhomocysteinemia is cystathionine 
B-synthase  deficiency13,54.  The  homozygous  form  of  this  disease  - 
congenital  homocysteinuria  -  is  associated  with  fasting  plasma 
homocysteine  levels  up  to  40  times  the  upper  limit  of  normal  (400 
umol/L);  methionine  concentration  in  plasma  is  also  elevated.  The 
homozygous trait  is  rare,  occurring in  only  1  in  200,000 births55.  Its 
clinical manifestations include skeletal deformities,  mental retardation, 
venous  thrombosis,  and  severe,  premature  atherosclerosis19. 
Homozygous persons frequently  develop atherosclerotic complications 
in  early  adulthood  that  are  often  fatal.   In  the  USA,  heterozygous 
deficiency  of  this  enzyme  occurs  in  1  of  300  births.  Heterozygous 
persons typically have plasma homocysteine levels in the range of 20 to 
40 umol/L;  patients  are usually  treated with vitamin B12,  betaine,  or 
both13,54,55.
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Homozygous  deficiency  in  N5,  N10-methylene  tetrahydrofolate 
reductase  (MTHFR)  may  also  lead  to  severe  hyperhomocysteinemia. 
Patients  with  severe  deficiencies  of  this  enzyme  may  have  variable 
phenotypes, such as developmental delay, motor and gait abnormalities, 
seizures; and psychiatric disturbances13. Pathologic changes observed in 
the severe form include the vascular changes found in conditions with 
elevated  homocysteine  and  reduced  neurotransmitter  and  methionine 
levels in the cerebrospinal  fluid.  A variant  of  this enzyme (decreased 
activity)  is  the  most  common  genetic  cause  of  mild 
hyperhomocysteinemia. Homozygosity of this mutant enzyme occurs in 
9% to 17% of the population, and this percent varies among different 
populations, and heterozygosity can be detected in 30% to 41% of the 
general population. Treatment of both disorders involves administration 
of vitamin B12, folic acid (Leucovorin), and betaine13,54. 
A much more rare disorder (cobalamin C disease) is caused by a 
congenital  deficiency  of  the  liver  enzyme  metyltetrahydrofolate 
homocysteine  methyltransferase  (methionine  synthase)  that  uses  folic 
acid and vitamin B12 to convert homocysteine to methionine. Clinical 
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manifestations  include  arteriolar  damage  and  accumulation  of 
homocysteine  and  cystathionine  in  the  urine.  Treatment  consists  of 
administration of vitamin B1213,54.
1.4 Acquired Disorders of Hyperhomocysteinemia:
Inadequate  plasma  concentrations  of  vitamin  B6,  and  vitamin 
B12,  and/or  folate,  contribute  to  nearly  two  thirds  of  all  cases  of 
hyperhomocysteinemia. Thus vitamin supplementation in these patients 
has  been  shown  to  effectively  reduce  elevated  plasma  homocysteine 
levels  and  may  improve  cardiovascular  morbidity  and  mortality.  In 
addition  to  vitamin  deficiencies,  several  therapeutic  drugs  have  been 
shown to affect homocysteine levels11,55. These compounds, along with 
their proposed mechanisms of action, are listed in Table (5) 5,11.
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Table (5). Drugs or Agents Known to Affect Plasma Homocysteine 
Level5, 11
Drug or Agent Proposed Mechanism
Increases plasma homocysteine
Anticonvulsant : Carbamazepine, 
phenobarbital, phenytoin, primidone, 
valporic acid  
Interfere with folate metabolism by 
impairing intestinal absorption, inducing 
hepatic enzymes that require and deplete 
folate, and interfering with metabolism of 
folate coenzymes.   
6-Azauridine Vitamin B6 antagonist 
Cyclosporine Possible folate antagonist; interferes with 
folate remethylations of homocysteine. 
Metformin Affects homocysteine homeostasis
Methotrexate Blocks folate cycle; dihydrofolate 
reductase inhibitor; reduces 5-
methyltetrahydrofolate .
Nitrous oxide Methionine synthase inhibitor; inactivates 
vitamin B12 cofactor
Theophylline Vitamin B6 antagonist 
( phosphodiesterase inhibitor of pyridoxal 
phosphate )
Decreases plasma homocysteine
D-penicillamine Forms mixed disulfides
Folic acid Enhances remethylation
Oral contraceptives Unknown
Tamoxifen Unknown
1.5 Homocysteine and Atherosclerosis
The “prothrombotic state” (any condition associated with a high 
frequency  of  thrombosis)  due  to  hyperhomocysteinemia  arises  from 
minor changes in homeostatic mechanisms. For example, homocysteine 
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increases  platelet  synthesis  of  thromboxane  A2  and  enhances  the 
expression of selectin, the platelet adhesion molecule;  both conditions 
cause  an  increase  in  platelet  adhesiveness  and  aggregation52,53,56. 
Homocysteine  may  also  produce  cytotoxic  endothelial  cell  injury, 
abnormalities in the blood clotting factors and fibrinolysis, and alteration 
of cholesterol and lipoprotein metabolism. Endothelial cell injury with 
subsequent platelet hyperactivity and the presence of abnormal clotting 
factors  may  contribute  directly  to  formation  of  thromboembolic 
obstructions  of  the  coronary,  carotid,  and  peripheral  arteries.  These 
obstructions  can  lead  directly  to  transient  ischemic  attacks  and 
eventually  coronary  heart  disease,  ischemic  stroke,  and  peripheral 
arterial disease, especially in elderly persons18,57.
The development of atherosclerosis and cardiovascular disease is 
a  continuous  process  that  occurs  at  several  stages,  beginning  with 
endothelial  injury  and  leading  to  smooth  muscle  proliferation.  When 
homocysteine accumulates in the blood, its metabolism becomes altered 
with  the  formation  of  a  major  by-product  called  homocysteine 
thiolactone. It has been proposed that homocysteine thiolactone reacts 
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with LDL to form so-called homocysteine thiolactone aggregates. These 
aggregates are sequestered by macrophages, and the resulting foam cells 
become  prevalent  in  atherosclerotic  plaques.  Within  these  plaques, 
homocysteine thiolactone can react with the various proteins, modifying 
the  oxidative  process  of  the  blood  vessels.  Auto-oxidation  of 
homocysteine  results  in  the  formation  of  superoxide  and  hydrogen 
peroxide,  which may contribute  to  the  oxidation of  LDL, endothelial 
dysfunction, and proliferation of vascular smooth muscle18, 58.
1.6 Homocysteine and Osteoporosis:
Osteoporosis is a disease of bone matrix. The process of normal bone 
formation is dependent on the collagen matrix, and requires the synthesis 
of collagen cross-links. The sulfhydryl group (- SH) of homocysteine 
interferes with the formation of these cross-link precursors of collagen, 
and thus the normal synthesis of collagen and bone formation. Patients 
with hyperhomocysteinemia and homocysteinuria develop osteoporosis 
at a higher rate than normohomocyteinemia subjects. The overall risk of 
developing osteoporosis in the presence of hyperhomocysteinemia has 
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been  reported  to  be  50%  by  age  16  years  among  homocysteinuria 
patients58,59.
1.7 Homocysteine and Other Degenerative Diseases 
Elevated homocysteine can be a sign of a methylation deficiency 
throughout the body. Methylation is fundamental  to DNA repaired. If 
DNA is not adequately repaired, mutations and strand breaks will result. 
This will lead to accelerated aging, as greater amounts of faulty proteins 
are  synthesized  from  the  damaged  DNA.  The  liver  depends  on 
methylation to  perform the numerous  enzymatic  reactions required to 
detoxify every drug and foreign substance that the body is exposed to. 
Methylation is also required for the growth of new cells. Without it, new 
cells cannot be made58.
A  study  published  in  the  Journal  Medical  Hypothesis  provides 
evidence  that  aging  may  be  exclusively  a  result  of  cellular 
“demethylation,” or, said differently, the aging process is caused by the 
depletion  of  enzymatic  “remethylation”  activity  that  is  required  to 
maintain and repair cellular DNA. This study suggests that aging may be 
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reversible if aged cells could be programmed to remethylate rather than 
demethylate60.
Homocysteine  induces  cellular  damage  by  interfering  with  the 
methylation process. Methylation will be compromised if homocysteine 
is  elevated,  and  elevated  homocysteine  is  a  warning  sign  that  the 
methylation cycle is not functioning properly. Homocysteine may also 
damage cells directly by promoting oxidative stress49, 60.
There  is  a  growing consensus  that  deficient  methylation  is  the 
major cause of the degenerative diseases of aging. The consumption of 
methylation-enhancing  nutrients  like  (Temporal  Gray  Matter)  TGM, 
choline,  folic  acid,  and  vitaminB12  may  be  one  of  the  most  readily 
available and effective anti-aging therapies presently known. However, 
it is important to tailor the intake of methylation-enhancing nutrients to 
one’s individual biochemistry. The best way of assessing one’s body rate 
of methylation is to measure blood level of homocysteine49.
1.8 Homocysteine and Alzheimer’s disease
Recent  studies  show  that  patients  with  dementia  of  the 
Alzheimer’s type have elevated levels of homocysteine in their blood.  
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While  scientists  speculated  that  Alzheimer’s  disease  could  be 
avoided if people reduced their homocysteine levels, it has not yet been 
determined  whether  homocysteine  itself  contributes  to  Alzheimer’s 
disease48. A more likely explanation is that elevated homocysteine is an 
indication  of  the  severe  disruption  in  the  methylation  pathway  that 
occurs in the brains of Alzheimer’s patients. It has been reported that 
people with Alzheimer’s disease have virtually no S-adenosylmethionine 
(SAMe)  in  their  brains.  SAMe  is  required  for  DNA  methylation 
(maintenance and repair) of brain cells. Thus, while homocysteine itself 
may not cause Alzheimer’s disease, it appears to represent an important 
measurable  biomarker  of  a  methylation  deficit  that  could  cause 
Alzheimer’s and a host of other degenerative diseases48,49,61.
1.9 Treatment of Hyperhomocysteinemia 
Elevated  levels  of  homocysteine  can  be  reduced or  normalized 
with dietary modifications and vitamin therapy, except in those patients 
with  severe  hyperhomocysteinemia.  Dietary  modifications  include 
minimizing methionine intake. Processed and refined foods should be 
kept  to  a  minimum,  as  should  foods  high  in  saturated  fats.  The  US 
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Department of Agriculture recommends 2 to 4 servings of fruit, 3 to 5 
servings of vegetables, and 6 to 11 servings of breads, grains, and pastas. 
Studies have shown that folic acid given at concentrations of 400ug or 
more daily can lower total homocysteine levels by 30% to 40%; vitamin 
B12 appears to be less effective, only lowering the total homocysteine 
level  by  15%;  pyridoxine  supplementation  is  least  effective,  in  the 
absence of vitamin B6 deficiency42,51.
Initial vitamin therapy includes folic acid and a multivitamin rich 
in vitamin B6 and B12; supplemental  therapy usually includes higher 
doses of vitamin B6 and B12.
For  resistant  cases  of  hyperhomocysteinemia,  betaine  and  choline 
therapy is added. Plasma levels of vitamin B12 and folic acid are often 
measured along with plasma concentrations of homocysteine to monitor 
the  effects  of  patient  therapy.  Vitamin  B6  however,  is  not  routinely 
measured3,51.
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 LABORATORY ASSESSSMENT OF 
HOMOCYSTEINE
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2.1 Measurement Methods:
Plasma  homocysteine  levels  can  be  measured  by  several 
techniques62:  acid  hydrolysis  followed  by  amino  acid  analysis,  high 
performance liquid chromatography (HPLC), gas chromatography- mass 
spectrometry  and  most  recently,  enzyme  immunoassay  (EIA)  and 
chemiluminescence’s competitive immunoassay (Bayer Method). Until 
the  development  of  enzyme  immunoassays,  HPLC  was  the  most 
common approach to homocysteine analysis62. Almost all homocysteine 
procedures are set up to measure total homocysteine. Only a few HPLC 
procedures  have  been  developed  to  measure  “free”  homocysteine 
(reduced  or  oxidized  forms  or  both);  these  require  lowering  the  pH 
(Acidification) as a pretreatment step. Most of HPLC procedures require 
(1) pretreatment of plasma with a reducing agent to convert disulfide 
forms such as homocysteine or cysteine-homocysteine to homocysteine 
and other thiols, (2) a derivatization step to form a fluorescent derivative 
with the - SH or amino (- NH2) group of homocysteine, (3) analysis with 
fluorometric  detection.  HPLC  methods  that  use  electrochemical 
detection do not require derivatization step63, 64, 65.
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A major disadvantage of HPLC analysis of homocysteine is that 
the methods are not standardized. This is not the case for the new EIA 
procedures. In fact,  the recent approval of two EIA methods by FDA 
will make the test available to many clinical laboratories. The Bio-Rad 
homocysteine EIA (Hercules, Calif), a solid phase immunoassay for the 
determination  of  total  homocysteine  in  plasma,  uses  the  Axis 
Biochemical’s ASA (Oslo, Norway) technique in which protein-bound 
homocysteine is reduced by dithiothreitol to free homocysteine, which is 
converted to S-adenosyl-L-homocysteine (SAH) by the enzyme SAH-
hydrolase and excess adenosine. Competition for the binding sites on an 
anti-SAH antibody takes place between SAH in the sample and SAH 
immobilized  on the microtiter  plate  walls.  After  removal  of  unbound 
anti-SAH  antibody,  a  secondary  antibody  labeled  with  horse-raddish 
peroxidase  is  added.  The  peroxidase  activity  is  measured 
spectrophotometrically  after  addition  of  substrate.  The  absorbance  is 
inversely proportional to the concentration of total homocysteine in the 
sample66.
53
The homocysteine  method by Abbot Laboratories  (Abbott  Park 
III) 67, 68 uses fluorescence polarization immunoassay in conjunction with 
the Abbott IMX; it also employs the patented Axis enzymatic conversion 
of  homocysteine to SAH. The three-step assay  includes (1)  reduction 
(with  dithiothreitol)  and  enzymatic  conversion  (SAH-hydrolase)  to 
produce SAH, (2) addition of the anti-SAH antibody, and (3) addition of 
the fluorescein tracer. The Bayer Chemiluminescence’s immunoassay is 
a competitive immunoassay using direct chemiluminescent technology. 
In  this  case  control  study,  total  homocysteine  was  measured  by  a 
chemiluminescence’s method (Bayer Health care Diagnostics Company) 
using the ACS-180 fully automated chemiluminescence’s system. The 
ACS-180 fully automated chemiluminescence’s assay is a competitive 
immunoassay  using  direct,  chemiluminescent  technology67,68.  The 
different forms of homocysteine in the patient samples were reduced to 
free  homocysteine  by  the  reducing  agent  dithiothreitol.  Free 
homocysteine is then converted to S-adenosylhomocysteine (SAH) by 
the enzyme SAH-hydrolase.  Converted SAH from the patient  sample 
competes with SAH covalently coupled to paramagnetic particles in the 
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solid phase for a limited amount of acridinium ester- labeled monoclonal 
mouse  anti-SAH  antibody  in  phosphate  buffer  with  bovine  serum 
albumin and preservatives.    Commonly used methods of homocysteine 
analysis, their characteristics, and their advantages and disadvantages are 
given in Table (6)63,64,65,66,67,68,69.
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Table (6). Characteristics of common Methods for Plasma Homocysteine 
Analysis 
Method / 
Reference
Principle of Method Plasma 
Volume 
( uL)
Preperation 
Time
*
Analysis Time
(10 samples)
* 
Reportable 
Range
(umol/L )
Comments
+
HPLC
Araki & 
Sako
TBP reduction , 
SBD-F 
derivatization 
500 90-120 
min
3-4 h 2 -65  A , D
Fermo et al NaBH4 
reduction , opA 
derivatization
200 60 -90 
min
5 h 0 - 320 A , B , D
Fiskerstrand 
et al
NaBH4 
reduction , 
mBrB 
derivatization
30 1 - 2 h 4 h 0.5 - 100 A , B , D
Dias et al 
( Bio-Rad )
TBP reduction, 
ABD-F 
Derivatization 
50 1 h 30 - 45 min 0.5 - 100 B , C , D 
Solomon & 
Duda ( BAS 
)
Proprietary 
reduction  and 
electrochemical 
detection
200 15 - 20 
min
100 min 2 - 60 E
EIA 
Frantzen et 
al ( Bio-Rad 
)
Reduction with 
DTT , 
homocysteine 
enzymatically 
converted to 
SAH, mesured 
by ELISA
50 2 h 30 - 45 min 2 - 50 C , F 
Alfheim et 
al 
(Abbott Imx 
)
Bayer 
Diagnostics.
Reduction with 
DTT , 
homocysteine 
enzymatically 
converted to 
SAH, mesured 
by FPIA,CHL. 
50 5 min 60 min 0 - 50  C , F 
ABD-F   indicates  4(aminosulfonyl)-7-fluoro-benzo-2-oxa-1,3-diazole;  DTT,  dithiothreitol;  EIA,  enzyme  immunoassay; 
ELISA, enzyme - linked Immunosorbent  assay;  FPIA,  fluorescence polarization immunoassay;  HPLC, high - performance 
liquid chromatography; mBrB, monobromobiman; NaBH4, sodium borohydride; opA, o-phthaldialdehyde; SAH,
 s-adenosylhomocysteine; SBD-F, ammonium-7- fluorobenzo-2-oxa-1,3-diazole-4-sulphonate; TBP, tri-n-butylphosphine.
* Preperation and analysis time are estimates, and may vary with degree of laboratory automation.
+ Advantages/disadvantages  :  A : indicates may be used to  analyze urine and other biological  samples;  B :  higher  assay 
linearity ; C : standardization of calibrators; D: labor-intensive sample preperation; E: no sample derivatization required; 
F : automated analysis, CHL: Chemilumeniscence’s Assay.
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2.2 Preanalytical Variables That May Affect Homocysteine 
Measurement:
2.2.1 Sample Transport and Processing
Homocysteine  is  highly  unstable  at  room  temperature  because 
RBCs produce and release homocysteine into the plasma compartment. 
Blood samples collected for homocysteine analysis should be kept cold 
and protected from light, and serum or plasma should be separated from 
cells as soon as possible.  Any delay in transport or processing of the 
sample will cause a spurious increase in plasma homocysteine. Plasma 
homocysteine increases by 10% within 1 hour and up to 75% in 24 hours 
if blood is stored at room temperature after collection62,70.
2.2.2 Collection Tubes:
Various anticoagulants - sodium heparin, sodium fluoride, EDTA- 
have  been  proposed  to  yield  the  blood  specimen  of  choice  for 
homocysteine determinations. Although EDTA is most commonly used, 
most  of  the  aforementioned  anticoagulants  do  not  inhibit  the  cellular 
production  of  homocysteine.  Sodium  fluoride  has  been  shown  to 
partially  inhibit  the  accumulation  of  homocysteine  in  blood.  Recent 
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studies,  however,  have  shown  that  this  anticoagulant  has  limited 
usefulness in preventing the export of homocysteine from cells69, 70.
When the collection tube contains acidic sodium citrate (pH 4.5) 
as the anticoagulant, however, the level of homocysteine appears to be 
more  effectively  maintained  after  blood  collection.  Although  acidic 
sodium citrate has been used in coagulation testing for many years, it is 
not FDA approved for homocysteine determination70, 71
2.3 Population Screening
Screening  for  hyperhomocysteinemia  should  be  considered  for 
persons with a strong family history of atherosclerotic disease, as well as 
those with early symptoms of coronary heart disease,  cerebrovascular 
disease, or peripheral vascular disease. Those patients are considered as 
high  risk  groups  for  CAD.  Patients  with  poor  nutritional  status 
(including  elderly  persons  and  chronic  abusers  of  alcohol  and  illicit 
drugs)  should  likewise  be  tested  for  plasma  homocysteine,  because 
dietary deficiencies of the essential micronutrients of homocysteine are 
common findings in these groups70,71,72.
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Chapter 3 
METHODOLOGIES AND 
TECHNIQUES:
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3.1 Study population:
A case control study was conducted from March 2004 to August 2004 at 
Ramallah  hospital  catheterization  laboratory.  Cases  and  one  control 
group were selected from patients aged 21 to 85 years who underwent 
coronary catheterization in Ramallah hospital catheterization laboratory. 
Patients  with  coronary  occlusions  (referred  to  as  cases)  or  without 
medically significant coronary occlusions (referred to as negative control 
subjects)  were included. A second control group was drawn from the 
general  population  from  subjects  without  history  of  cardiovascular 
diseases  (referred  to  as  population-based  control  subjects).Exclusion 
criteria from all groups were cancer, alcohol or drug abuse, B vitamin 
supplementation and psychiatric illness.
During  the  above  mentioned  period  318  patients  attend  the 
Catheterization  unit  at  Ramallah  hospital  for  cardiac  catheterization. 
From those 318 patients 292 were accepted to this case control study, the 
other  16 patients  were  rejected  due to  such conditions  like intake of 
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psychiatric drugs, vitamins,  and nonfasting.  All the 292 patients were 
catheterized.   
At catheterization, projections were made of the major coronary vessels, 
which  are  the  left  main  coronary  artery,  the  left  circumflex,  the  left 
anterior descending, the right coronary artery and the aorta.
A cardiologist reviewed the projections and prepared the catheterization 
report.  Cases  were  defined  as  those  having  ≥  50% occlusion  in  any 
coronary artery and those were 189 patients. Coronary control subjects 
who  were  defined  as  those  having  <50% occlusion  in  any  coronary 
artery were 103 patients.
The conditions that led to catheterization were mainly angina pectoris 
and a known cardiac or valve disease in some patients. One hundred and 
two cases (51.1%) and thirteen negative control subjects (7.7%) had a 
history of myocardial infarction before catheterization. In the coronary 
control subjects, myocardial infarctions were due to coronary spasms or 
other nonatherosclerotic causes. Since atherosclerosis was the end point 
of interest, these control subjects were not excluded from the study. 
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The population-based control group was obtained from different places 
like Ministry of Labor, Ministry of Finance, colleges and universities. 
Before the day of blood collection all those who agreed to participate in 
the study were informed that they should fast completely for at least 12 
hours before withdrawal of blood, and they should fast for 24 hours the 
day before blood phlebotomy from lipids. All of them were not suffering 
or have been treated for cardiac problems, diabetes, or any other major 
disease that may affect the study. Participants, males and females age 
from 21 to 85 years of old are only accepted to participate. Thus, a total 
of 126 population-control subjects were accepted to share, from them 
only 96 subjects were included in the study. The reminder 30 subject 
were refused because they inform us that they are taken medications for 
some cardiac problems.
All participants gave their written informed consent as medical  ethics 
protocols emphasize.
3.2 Data Collection: 
History  of  angina,  hypertension,  diabetes,  family  history  of 
premature  CAD,  other  medical  problems,  medications,  lipid lowering 
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diets,  smoking  history  and  history  of  vascular  events  (myocardial 
infarction,  cerebrovascular  disease,  peripheral  vascular  disease)   was 
collected through a questionnaire to the three groups of cases.
3.3 Blood sampling and examination:
 At the day of catheterization, venous blood samples were obtained 
from  all  subjects  between  8:30  AM  and  9:30  AM  after  10-12hours 
fasting. Two types of samples were obtained one was EDTA blood to 
measure tHcys, the other was plain sample to measure total Cholesterol, 
HDL-C, Triglycerides, and LDL-C.
EDTA blood for measurement of tHcy was placed on ice and in the dark 
immediately and centrifuged at 4ْC within 1 hour to avoid false elevation 
caused  by  the  release  of  homocysteine  from  RBCs,  a  process  that 
continues  at  room temperature.  Once  the  plasma was  separated  from 
cells,  it  was  stored  refrigerated  at  -20ْ  C  for  several  weeks  before 
analysis.
3.4 Biochemical Analysis:
Cholesterol,  HDL-C,  LDL  and  Triglycerides  was  measured 
spectrophotometrically  using  commercial  kits.  The  kits  were  from 
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Diasys  Company  (Germany).  Cholesterol  was  measured  using  the 
cholesterol oxidase method (CHOD). HDL and LDL were measured by 
the  direct  precipitation  techniques  then  LDL-cholesterol,  HDL-
cholesterol were measured. Triglycerides were measured by colorimetric 
enzymatic  test  using  glycerol-3-phosaphate  oxidase  (GPO).  The 
reference  intervals  for  these  biochemical  markers  were  considered 
according to WHO standards.
Platelets counts, MPV, BUN, and Creatinine were registered from 
the patients’ medical file, all of which were done the day before the day 
of the catheterization.
Total  homocysteine  was  measured  by  a  chemiluminescence’s  method 
(Bayer  Health  care  Diagnostics  Company)  using  the  ACS-180  fully 
automated chemiluminescence’s system. The ACS-180 fully automated 
chemiluminescence’s assay is a competitive immunoassay using direct, 
chemiluminescent technology. The different forms of homocysteine in 
the patient samples were reduced to free homocysteine by the reducing 
agent  dithiothreitol.  Free  homocysteine  is  then  converted  to  S-
adenosylhomocysteine (SAH) by the enzyme SAH-hydrolase. Converted 
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SAH from the patient sample competes with SAH covalently coupled to 
paramagnetic  particles  in  the  solid  phase  for  a  limited  amount  of 
acridinium  ester-  labeled  monoclonal  mouse  anti-SAH  antibody  in 
phosphate buffer with bovine serum albumin and preservatives. 
An  inverse  relationship  exists  between  the  amount  of  homocysteine 
present  in  the  patient  sample  and  the  amount  of  relative  light  units 
detected by the system.
For homocysteine, studies have not yet definitively established reference 
standards  by  age  category  and  gender,  although  these  variables  are 
known to affect homocysteine levels. Men have higher concentrations of 
homocysteine  than  women,  and  amounts  of  homocysteine  tend  to 
increase with age.
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HOMOCYSTEINE
Proposed Cut-off Values For Homocysteine in 
Clinical Decision Making
The figure indicates different cut -off values for homocysteine . The color-shift from green to red indicates the 
increasing urgency of clinical decision making and actions.
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Fig.3. Proposed cutoff values for homocysteine in clinical use70. 
As  shown  in  Figure  3  above  it  may  be  more  clinically  relevant  to 
identify a “relative risk range “for homocysteine concentrations, rather 
than precise reference intervals (analogous to the manner in which serum 
cholesterol  values  are  now  interpreted).  In  general,  a  plasma 
homocysteine concentration of 10umol/L or less is considered optimal. 
A  plasma  homocysteine  level  of  10  to  12  umol/L  is  considered 
borderline,  while a concentration above 12 umol/L is associated with 
high risk of occlusive vascular disease.
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DATA ANALYSIS
Data Analysis:
Smoking status, hypertension, cholesterol, triglycerides, HDL, and LDL 
levels were determined at the time of the investigation. Current smoking 
was defined as the use of any tobacco. In addition, duration of smoking 
per  years  and  amount  of  cigarettes  smoked  (packs  per  day)  was 
calculated. Subjects were diagnosed as hypertensive at a systolic blood 
pressure ≥ 160mmHg or diastolic blood pressure ≥90 mm Hg or when 
they were using antihypertensive drugs.
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Hypercholesterolemia was defined as serum cholesterol ≥ 200 mg% or 
use of cholesterol lowering drugs.
Differences in mean values of cardiovascular risk factor levels between 
cases and control subjects were tested with Students t-test for continuous 
variables  and  Chi-Square  test  for  frequency  measures.  To  evaluate 
potential  confounding,  associations  of  the  cardiovascular  risk  factors 
were studied with plasma total homocysteine levels among the combined 
control groups by calculating Chi-square.
Means  and  Standard  Deviations  (SDs)  of  age,  total  homocysteine, 
cholesterol,  and  triglycerides,  HDL,  LDL,  BUN and  Creatinine  were 
calculated for all three studied groups.
By  means  of  logistic  regression  analysis,  the  (Odd  Ratios)  ORs  for 
severe coronary atherosclerosis (case status) were calculated for those 
with elevated total homocysteine levels of the combined control groups. 
ORs were considered to estimate relative risks of subjects. To evaluate a 
possible graded association of plasma total homocysteine with coronary 
atherosclerosis, the ORs were computed for different results of cardiac 
catheterization. Also, the ORs were calculated for elevated fasting total 
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homocysteine,  based  on  previously  established  cutoff  points  (14.0 
umol/L,  cutoff  points  of  Stampfer,  and 15.8 umol/L,  cutoff  points  of 
Selhub)5,11,42. 
To  study  whether  total  homocysteine  was  related  to  the  number  of 
significantly occluded coronary arteries, all the 292 catheterized patients 
were grouped into five groups (1,2,3,4,5) according to number of arteries 
occluded. All reported probability values are two tailed.
Chapter 5
RESULTS
70
5.1 Characteristics of Study Groups:
Tables (7) and (8) show characteristics of the cases and the two control 
groups at the time of catheterization. The percentage of males and mean 
age were higher in cases than in both control groups. The majority of 
subjects in all groups were aged 21 to 85 years. Mean total cholesterol 
levels,  HDL cholesterol  levels,  BUN, creatinine  and LDL cholesterol 
levels were similar among the groups. The proportion of hypertension 
among subjects was higher among population control subjects than the 
other  two  groups.  Mean  serum  level  of  triglycerides  was  highest  in 
population control  subjects,  but  this  could be explained in  that  those 
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subjects were not strictly committed to the test instructions concerning 
fasting hours and nutrition habits before  the test.  So,  if  this were the 
case, mean serum triglycerides in cases will be the highest. At the time 
of examination,  a lower percentage of cases were smoking,  but mean 
years of smoking was highest in cases. Uric acid concentrations were 
highest in cases in comparison to the other groups of subjects.
Table 7. Characteristics of Cases and two groups of control subjects for 
continuous variables.
Cases
N=(189(
X±SD
Negative Control 
Subjects N=(103) 
X±SD
Population 
Control Subjects 
N=(96(
X±SD
Age , 56.3±12.0 47.8±8.4 43.9±9.9
Total Cholesterol,mg% 195.6±52.6 185±36.8 188.9±51.3
HDL-Cholesterol,mg% 44.4±18.4 42.3±13.1 43.5±16.7
LDL-Cholesterol,mg% 129.6±50.9 117.3±33.9 117.9±47.7
Triglycerides,mg% 137.8±83.6 121.1±68.7 146.3±84.5
BUN, mg% 20.5±8.2 19.3±4.6 20.0±7.0
Creatinine, mg% 0.91±0.28 0.94±0.26 0.95±0.25
Uric acid,mg % 6.8±1.9 6.0±1.8 5.9±1.3
Platelets /thousand/uL 255±78 251±54 253±57
MPV 9.8±1.6 9.7±1.0 8.2±1.0
Table 8: Characteristics of Cases and two groups of control subjects for 
other variables.
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Cases
N=(189(
Negative Control 
Subjects N=(103(
Population 
Control Subjects 
N=(96(
Male% 75.1% 79.6% 77.1%
Female% 24.9% 20.4% 22.9%
Hypertension% 44.4% 37.9% 0.6%
Currently Smoking% 36.4% 35.0% 38.5%
Ex-smoking% 36.2% 14.9% 14.6%
 
5.2  Plasma  Total  Homocysteine  Concentration  of  Study 
Groups:
5.2.1 Patients versus Negative Control Group:
To  study  the  effect  of  sex  on  Hcy  concentration  between  these  two 
groups t-test was calculated and it was found that there is no statistical 
significance between males and females in Hcy concentration as shown 
in Table(9), P=0.945.
Table (9): Hcy concentration among males and females in patients and 
negative control groups.
Males Females
Patients
Hcy (Mean ± SD) umol/L
142
20.8±8.8
47
20.7±10.6
Negative Control Group
Hcy (Mean ± SD) umol/L
82
14.4±4.4
21
14.0±4.4
Hcy (Mean ± SD) umol/L 18.5±8.2 18.6±9.6
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Also,  when  results  of  cardiac  catheterization  (number  of  occluded 
arteries  were studied  among these  two groups  by using t-test,  it  was 
found that there is a statistical significance between those who have any 
coronary artery disease( occlusion of any coronary artery) and those who 
are normal,  P= 0.00.But it was calculated that there was no statistical 
significance between those who have single artery disease and double 
artery  disease,  P=0.816,  and  between  those  who  have  double  artery 
disease and triple artery disease, P= 0.996.These results imply that there 
is  no  strong  association  between  Hcy  concentration  and  number  of 
occluded arteries, the association is variable.
To study the risk estimate of CAD among patients and negative control 
subjects, all patients were grouped into two groups according to Selhub 
Hcy cutoff value, Stampfer Hcy cutoff value and my established cutoff 
value, then multinomial logistic regression was calculated to obtain the 
ORs  before  age,  sex  and  other  confounders  adjustments  and  after 
adjustments. The results are shown below in the Tables 10 and 11.
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Table  10:  ORs  among  patients  and  Negative  Control  subjects  for 
Hyperhomocysteinemia  using  different  cutoffs  for  Hcy  before 
adjustment  for age, sex,  Hypertension, cholesterol,  triglycerides,  HDL 
and LDL.
By using Selhub Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 42 147
40.0 0.00 5.08 3.02-8.56
Negative 
Controls
61 42
By Using Stampfer Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 68 121
30.7 0.00 4.13 2.47-6.92
Negative 
Controls
72 31
By Using established Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 52 137
35.2 0.00 4.51 2.70-7.52
Negative 
Controls
65 38
75
Table  11:  ORs  among  patients  and  Negative  Control  subjects  for 
Hyperhomocysteinemia using different cutoffs for Hcy after adjustment 
for age, sex, Hypertension, cholesterol, triglycerides, HDL and LDL.
By using Selhub Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 42 147
49.0 0.00 5.26 3.01-9.21Negative 
Controls
61 42
By Using Stampfer Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 68 121
46.0 0.00 4.65 2.64-8.19Negative 
Controls
72 31
By Using established Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 52 137
35.2 0.00 4.84 2.77-8.44Negative 
Controls
65 38
5.2.2 Patients versus Population (Random) Control Group:
To  study  the  effect  of  sex  on  Hcy  concentration  between  these  two 
groups t-test was calculated and it was found that there is no statistical 
significance between males and females in Hcy concentration as shown 
in Table(12), P=0.553.
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Table(12): Hcy concentration among males and females in patients and 
Population control groups. 
Males Females
Patients
Hcy (Mean ± SD) umol/L
142
20.8±8.8
47
20.7±10.6
Population Control Group
Hcy (Mean ± SD) umol/L
74
15.6±5.0
22
13.5±3.0
Hcy (Mean ± SD) umol/L 19.1±8.1 18.4±9.5
Also,  when  results  of  cardiac  catheterization  (number  of  occluded 
arteries  were studied  among these  two groups  by using t-test,  it  was 
found that there is a statistical significance between those who have any 
coronary artery disease( occlusion of any coronary artery) and those who 
are normal,  P= 0.00.But it was calculated that there was no statistical 
significance between those who have single artery disease and double 
artery  disease,  P=0.816,  and  between  those  who  have  double  artery 
disease and triple artery disease, P= 0.996.These results also imply that 
the  association  between  Hcy  concentration  and  number  of  occluded 
arteries, is variable, and this is the same for negative control subjects. All 
these  results  increase  the  assumption  that  these  two  control  groups 
should be treated as one single control group which was done in the 
forward studies and calculations.
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To  study  the  risk  estimate  of  CAD  among  patients  and  population 
control subjects, all patients were grouped into two groups according to 
Selhub Hcy cutoff value, Stampfer Hcy cutoff value and my established 
cutoff  value,  then  multinomial  logistic  regression  was  calculated  to 
obtain the ORs before age, sex, cholesterol, triglycerides, HDL and LDL 
adjustments and after adjustments. The results are shown below in the 
Tables 13 and 14.
Table  13:  ORs  among  Patients  and  Population  Control  subjects  for 
Hyperhomocysteinemia  using  different  cutoffs  for  Hcy  before 
adjustment for age, sex, cholesterol, triglycerides, HDL and LDL.
By using Selhub Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 42 147
10.6 0.001 2.40 1.41-4.10
Population 
Controls
39 57
By Using Stampfer Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
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Patients 68 121
21.2 0.00 3.25 1.94-5.42
Population 
Controls
62 34
By Using established Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 52 137
12.9 0.00 2.53 1.52-4.22
Population 
Controls
47 49
Table  14:  ORs  among  Patients  and  Population  Control  subjects  for 
Hyperhomocysteinemia using different cutoffs for Hcy after adjustment 
for age, sex, cholesterol, triglycerides, HDL and LDL.
By using Selhub Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 42 147
37.9 0.001 2.25 1.24-4.08
Population 
Controls
39 57
By Using Stampfer Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 68 121
45.7 0.00 2.95 1.65-5.28
Population 
Controls
62 34
By Using established Cutoff of Hcy
Normal 
Hcy
Hyper. 
Hcy
X2 P OR CI 95%
Lower-Upper
Patients 52 137
40.0 0.00 2.39 1.33-4.28
Population 
Controls
47 49
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For  all  study  groups,  mean  levels  of  plasma  total  homocysteine 
concentration and standard deviation were calculated. The mean levels 
of plasma total homocysteine were higher in cases compared to the other 
two groups, (P=0.00). While for the two control groups there were no 
statistical  significance  in  mean  homocysteine  concentrations  between 
them,(P=0.728).Also  distributions  of  total  Homocysteine  levels  were 
very  similar  among  negative  control  patients  and  population  control 
subjects as shown in Figures 4 and 5. Therefore, these two groups were 
combined in all subsequent analysis as one negative control group. So, 
when dealing with these two groups there is a statistically significant 
difference  between  them  in  the  mean  homocysteine  concentration, 
(P=0.00).   Cases  had  statistically  higher  mean  levels  of  fasting  total 
homocysteine as shown in Table (15).
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Table  15:  Plasma  Total  Homocysteine  among  cases  and  two control 
groups.
Cases
N=(189)
Negative Control 
Subjects N=(103)
Population 
Control Subjects 
N=(96)
Mean±SD Mean±SD Mean±SD
Fasting t-Hcy,umol/L 20.8±9.3 14.3±4.4 15.2±4.7
Also,  as  Figure  (6)  shows,  the  higher  mean  levels  of  fasting  total 
homocysteine in cases were a consequence shift toward the left of the 
cases  frequency distribution.  For  fasting  total  homocysteine,  this  was 
slightly more consistent throughout the entire distribution.
Homocysteine Concentration (umol/L(
26.0
25.0
24.0
23.0
22.0
21.0
20.0
19.0
18.0
17.0
16.0
15.0
14.0
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10.09.0
  Negative Control Subjects
30
20
10
0
Std. Dev = 4.36  
Mean = 14.3
N = 103.00
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Figur4.  Frequency  distribution  of  plasma  total  Homocysteine  among 
Negative Control Patients.
Figure 5. Frequency distribution of plasma total Homocysteine among 
Population Control Patients.
      Homocysteine Concentration (umol/L(
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Figure 6. Frequency distribution of plasma total Homocysteine among 
Cases.
Also it’s worth here to mention that if we consider the negative controls 
(n=103) as cases (n=189) since those negative controls are considered 
atherosclerotic patients regardless of the degree of stenosis in their 
arteries, we will find that there is a statistically significant difference 
between this new grouping of cases and population control group 
regarding the mean Hcy concentration as shown in Table (16), P=0.000. 
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Table (16): Mean Plasma Total Hcy among new formulated cases (cases 
+ negative controls) and population control groups.
Cases
 ( n=292)
Population Control 
Group ( n=96)
Mean±SD Mean±SD
Fasting t-Hcy,umol/L 18.5±8.5 15.2±4.7
Furthermore, by using the new arrangement of the cases as mentioned in 
table (16) if we calculate the ORs and X2 test  for these two groups using 
the three cutoff values for Hcy( Selhub, Stampfer,and my cutoff values), 
the following results were obtained.
From Table(17) it's clear that there is only statistical significance in 
hyperhomocysteinemia when using Stampfer cutoff, P=0.005, but for the 
other cutoffs there is no statistical significance.
When ORs for these two groups were calculated by logistic regression, 
the following results where obtained.
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Table (17): Comparison of Hyperhomocysteinemia between Cases and 
Negative Controls.
Risk Factors Case Groups
Patients Controls
(n=292)   (n=96)
Patients 
vs. 
Controls 
(x2)
P 
Value
Hyperhomocysteinemia
( Stampfer Cutoff)
Absent 140 62 8.00 0.005
Present 152 34
Hyperhomocysteinemia
( Selhub Cutoff)
Absent 103 39 0.892 0.393
Present 189 57
Hyperhomocysteinemia
( Established Cutoff)
Absent 117 47 2.34 0.153
Present 175 49
Table (18): ORs for Cases and negative controls according to Hcy mean 
concentration using different cutoff values.
Homocysteine Result Cutoff used OR 95% CI
Lower - Upper
Normal Hcy -Hyper Hcy Stampfer 0.505 0.313 - 0.814
Selhub 0.796 0.496 - 1.278
Established 0.697 0.438 – 1.11
   
 
5.3 Plasma Total Homocysteine and Risk of Coronary 
Artery Occlusion:
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The mean and standard deviation of total homocysteine were calculated 
for each result of catheterization obtained from the different study 
groups. Results are shown in Table (19) below.
Table19: Mean and SD of Total Plasma Homocysteine according to 
catheterization results.  
Catheterization 
Result
Number of 
Patients
Fasting Total Hcy, umol/L
Mean ± SD
Normal 105 14.40 ± 4.4
Occlusion of 1 Artery 45 19.01 ± 7.6
Occlusion of 2 Arteries 60 19.30 ± 6.6
Occlusion of 3 Arteries 57 19.30 ± 7.1
Occlusion of 4 Arteries 19 33.5 ± 15.4
Other CVD 6 24.5 ± 11.1
Unknown 96 15.20 ± 4.7
From these results it was shown that for those patients who have 1, 2, or 
3 occluded arteries there is no significant difference in the mean of total 
homocysteine (P=0.816). Whereas, in those who have 4 occluded 
arteries there is a significant rise in the mean compared to the other 
groups or to the normal level of homocysteine, (P=0.00). Also, the other 
two groups of this case controlled study, the population controlled group 
and the negative one; there is no significant difference between the 
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means of the total homocysteine concentration among both of these 
groups, (P= 0.728).
Table (20) shows ORs for severe coronary atherosclerosis for patients 
and controls with total homocysteine using the three mentioned cutoff 
values for homocysteine before adjustment for age, sex, and other 
confounders. These odd ratios mentioned in the table below show the 
increased risk of having a coronary artery occlusion with 
hyperhomocysteinemia in all the proposed cutoffs for homocysteine. 
Also, these ORs show that increase in homocysteine concentrations 
increases the number of occluded arteries.
Considering the coronary artery disease as the net outcome of occluded 
arteries, this outcome when its association with hyperhomocysteinemia 
was measured statistically by logistic regression using the established 
cutoff from this study (Homocysteine=14.7 umol/L ± 4.52), the OR was 
3.267(95% CI, 2.1 – 5.0). The OR for an increase of 1SD in plasma total 
homocysteine was 6.70, (95%CI, 4.10 – 10.86) before adjustment for 
age, sex and other confounders, and OR was 8.21 (95% CI, 4.14 – 16.3) 
after adjustment for age, sex, cholesterol, triglycerides, HDL and LDL.
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Also, as shown in Table (21), there were no statistical association after 
adjusting for age, sex, cholesterol, triglycerides, HDL and LDL.
Table 20. Odd Ratios of severe coronary atherosclerosis for patients and 
controls using Selhub cutoff, Stampfer Cutoff, and established cutoff 
values for Homocysteine concentrations, before adjustment for age, sex, 
cholesterol, triglycerides, HDL and LDL.
Catheterization Result Cutoff used OR 95% CI
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Lower - Upper
Normal-Single artery Disease Selhub 3.06 1.47 - 6.38
Stampfer 4.00 2.02 - 7.94
Established 3.10 1.54 – 6.25
Normal-Double artery Disease Selhub 3.96 1.99 – 7.90
Stampfer 3.46 1.89 – 6.30
Established 3.46 1.83 – 6.54
Normal- Triple artery Disease Selhub 2.77 1.45 – 5.32
Stampfer 2.96 1.62 – 5.41
Established 2.52 1.36 – 4.67
Normal – Four artery disease Selhub 3.71 1.19 – 11.58
Stampfer 4.33 1.58 – 11.91
Established 4.72 1.51 – 14.72
Table 21. Odd Ratios of severe coronary atherosclerosis for patients and 
controls using Selhub cutoff, Stampfer Cutoff, and established cutoff 
values for Homocysteine concentrations, after adjustment for age, sex,
cholesterol, triglycerides, HDL and LDL.
Catheterization Result Cutoff used OR 95% CI
Lower - Upper
Normal-Single artery Disease Selhub 2.22 0.846 – 5.84
Stampfer 2.31 0.915 – 5.85
Established 2.05 0.809 – 5.2
Normal-Double artery Disease Selhub 2.92 1.30 – 6.54
Stampfer 2.13 1.01 – 4.53
Established 2.35 1.09 – 5.05
Normal- Triple artery Disease Selhub 2.22 0.950 – 5.21
Stampfer 2.24 0.990 – 5.08
Established 2.17 0.850 – 12.9
Normal – Four artery disease Selhub 3.31 1.34 – 4.02
Stampfer 4.33 1.58 – 11.9
Established 5.09 1.16 – 22.21
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5.4 Catheterization Results among Different groups 
According to Sex:
By using the Chi-square test there was no  statistically significant 
difference between males and females in all the studied groups in the 
number of arteries occluded or the catheterization results as shown in 
Table(22) below, (x2 =4.1, P=0.536).
Table (22): Results of Catheterization among males and females in all 
groups.
Catheterization Results
Normal Single 
Artery 
Disease
Double 
Artery 
Disease
Triple 
Artery 
Disease
Four 
Artery 
Disease 
Other 
Cardiac 
Disease
Males 156 36 46 41 16 3
Hcy.
Mean ±SD
15.0±4.7 19.8±7.8 20.2±6.5 18.8±6.2 30.9±15.5 19.0±5.5
Females 45 9 14 16 3 3
Hcy.
Mean ±SD
13.9±3.7 15.9±5.9 16.5±6.1 20.7±9.0 46.9±2.6 30.0±13.7
P 0.146 0.173 0.067 0.368 0.099 0.265
 Also, T-test shows no significant difference between males and females 
in homocysteine concentration in all studied groups as shown in Table 
(22). Furthermore, statistically it was found that there is statistical 
significance between the concentration of homocysteine in normal 
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patients and those who have any cardiac problem (P=0.008) which 
increases the evidence that homocysteine may be a marker worth 
considering in coronary artery and other vascular diseases. Also, we can 
find that there is no statistical significance between the results of 
catheterization and homocysteine concentration in the patients who 
didn’t undergo catheterization (population control group) and those who 
have normal results in catheterization ( P= 0.139). This evidence 
increases my assumption that those two populations of patients 
(Population control group and Negative control group) should be treated 
as one group (Negative control group).
5.5  Comparison  of  Risk  Factors  between  Patients  and 
Controls: 
5.5.1 Comparison  of  Risk Factors Between Patients  and Negative 
Control Subjects.
Table  (23)  Comparison  of  risk  factors  between patients  and negative 
control subjects.
Risk Factors Case Groups
Patients Controls
Patients 
vs. 
P 
Value
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(n=189)   (n=103) Controls 
(x2)
Hyperhomocysteinemia
( Stampfer Cutoff)
Present 121 31 30.7 0.000
Absent 68 122
Hyperhomocysteinemia
( Selhub Cutoff)
Present 147 62 39.9 0.001
Absent 42 42
Hyperhomocysteinemia
( Established Cutoff)
Present 137 38 35.2 0.000
Absent 52 65
Hypercholesteremia Present 80 41 0.378 0.617
Absent 102 61
Smoking Present 68 36 0.058 0.898
Absent 119 67
Ex-Smoking Present 67 15 14.6 0.000
Absent 118 86
Hypertension Present 84 39 2016 0.177
Absent 68 47
Diabetes Mellitus Present 56 39 1.86 0.214
Absent 96 46
From this  comparison it  was clear  that  for  the three cutoffs  used for 
homocysteinemia  there is  statistical  significance  between patients  and 
negative controls.
But for the other risk factors there was no significant difference between 
the two groups except for ex-smokers which was statistically significant.
5.5.2 Comparison of risk factors between Patients and Population 
Control Subjects.
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Risk factors between population control groups and patients was studied 
for statistical significance to compare their significance with the negative 
control group. Results of this comparison and statistical significance are 
mentioned in Table (24).
From this Table it was seen that the similar exists between risk factors in 
the two groups compared to the other two groups in Table (23). These 
results  mean  that  there  is  no  statistical  difference  between  the  two 
control  groups  which  increases  my  assumption  to  study them as  one 
control group. But its worth to mention here that significance between 
these two groups exists only for DM where there is a difference.  
  
Table (24) Comparison of risk factors between patients and population 
control subjects.
Risk Factors Case Groups
Patients Controls
(n=189)   (n=96)
Patients 
vs. 
Controls 
(x2)
P 
Value
Hyperhomocysteinemia
( Stampfer Cutoff)
Present 121 34 21.0 0.000
Absent 68 62
Hyperhomocysteinemia
( Selhub Cutoff)
Present 147 39 10.6 0.001
Absent 42 57
Hyperhomocysteinemia Present 137 49 12.9 0.001
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( Established Cutoff) Absent 52 47
Hypercholesteremia Present 80 42 0.001 1.00
Absent 102 54
Smoking Present 68 37 0.129 0.795
Absent 119 59
Ex-Smoking Present 67 14 14.4 0.000
Absent 118 82
Hypertension Present 84 6 4.52 0.056
Absent 68 14
Diabetes Mellitus Present 56 14 13.1 0.000
Absent 96 3
Table  (25)  shows  that  there  is  a  statistical  significant  association 
between  the  two control  groups  in  homocysteine  mean  concentration 
using Selhub cutoff value for Hcy (P=0.011), and my established cutoff 
value (P=0.047). While it was insignificant when using Stampfer cutoff 
value (P=0.452).
For  the  other  risk  factors  and  confounders  there  is  no  statistical 
significance between them except for DM (P=0.007).
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Table (25) Comparison of risk factors between negative and population 
control subjects.
Risk Factors Case Controls
Négative Population
(n=103)   (n=96)
Patients 
vs. 
Control
s  (x2)
P 
Value
Hyperhomocysteinemia
( Stampfer Cutoff)
Present 31 34 0.639 0.452
Absent 72 62
Hyperhomocysteinemia
( Selhub Cutoff)
Present 42 57 6.88 0.011
Absent 61 39
Hyperhomocysteinemia
( Established Cutoff)
Present 38 49 4.04 0.047
Absent 65 47
Hypercholesteremia Present 41 42 0.257 0.666
Absent 61 54
Smoking Present 36 37 0.276 0.660
Absent 67 59
Ex-Smoking Present 15 14 0.003 1.00
Absent 86 82
Hypertension Present 39 6 1.57 0.315
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Absent 47 14
Diabetes Mellitus Present 39 14 7.55 0.007
Absent 46 3
 
 5.5.3 Comparison  of  Risk Factors  between Patients  and Control 
Subjects.
From all the previous analysis of data and results, and since there were 
no  significant  differences  in  most  of  the  factors  and  characteristics 
between the two control  groups,  the two groups were merged in one 
control group. All the statistical analysis will consider one patients group 
(Cases) and one control group (Controls).
The statistical comparison between patients and controls are summarized 
in Table (26), that shows statistically significant difference between the 
two groups for hyperhomocysteinemia using Stampfer cutoff (p=0.00) 
and Selhub cutoff (p=0.00).A statistically significant difference was not 
noted  between  patients  and  controls  for  smoking  (p=1.00)  while  the 
significance exists for ex-smokers (p=0.00).
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Table 26. Comparison of Risk Factors between Patients and Controls:
Risk Factors Case Groups
Patients Controls
(n=189)   (n=199)
Patients 
vs. 
Controls 
(x2)
P 
Value
Hyperhomocysteinemia
( Stampfer Cutoff)
Present 121 65 38.2 0.000
Absent 68 134
Hyperhomocysteinemia
( Selhub Cutoff)
Present 147 99 32.8 0.000
Absent 42 100
Hypercholestermia Present 80 83 0.161 0.756
Absent 102 115
Smoking Present 68 73 0.004 1.00
Absent 119 126
Ex-Smoking Present 67 29 23.4 0.00
Absent 118 168
Hypertension Present 84 45 4.1 0.053
Absent 68 57
Diabetes Mellitus Present 56 53 5.7 0.020
Absent 96 49
However,  statistically  significant  difference  was  observed  between 
patients  and  controls  for  diabetes  mellitus  (p=0.020).But  for 
hypertension  and  hypercholesteremia  there  was  no  statistical 
significance  between  patients  and  controls,(  p=0.756)  and(  p=0,053) 
respectively.
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Table (27) shows the association of hyperhmoocysteinemia with other 
risk  factors  among  patients,  using  established  cutoff  value  for 
homocysteine from this study. To evaluate the statistical significance of 
hyperhomocysteinemia  with  these  risk  factors,  patients  were  grouped 
into  two groups,  group A represents  those  patients  who have  Hcy > 
14.7umol/L, while group B represents those who have Hcy<14.7 umol/L 
then Chi-square test was calculated.
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Table (27): Association of hyperhomocysteinemia with other risk factors 
among patients  (n=207),  using my cutoff  for  homocysteine (14.7±4.5 
umol/L).
Risk factors Group A 
(n=137) 
Hcy>14.7 
umol/L 
Group B 
(n=70) 
Hcy<14.7 
umol/L
Group A 
Vs.
Group B
X2
p-Value
Hypercholesteremia 46 34 14.84 0.000
Hypertension 54 51 2.02 0.164
Diabetes Mellitus 33 23 4.77 0.046
Smoking 46 22 1.10 0.312
Ex-Smoking 52 15 1.15 0.307
Sex: Males 107 53 2.35 0.135
        Females 30 17
Hypercholesteremia and Diabetes Mellitus were statistically significant 
with hyperhomocysteinemia in all the proposed cutoff values used for 
homocysteine; p-values for them were mentioned in tables 15,and 16. 
However, there is no statistical difference between males and females in 
association  with  hyperhomocysteinemia  (P=0.051,  P=0.164,  P=0.135) 
respectively in the three cutoff values used, Selhub, Stampfer, and my 
case control study cutoffs. Although smoking is one of the risk factors 
associated with hyperhomocysteinemia, according to my study, there is 
no  statistical  significance  between  smokers,  nonsmokers,  and  ex-
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smokers. Hypertension was statistically significant when using Stampfer 
cutoff  (p=0.019),  and  my  study  cutoff  (p=0.00),  while  it  was 
insignificant when using Selhub cutoff (p=0.190). 
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Chapter 6
DISCUSION
Discussion:
My  study  findings  support  the  hypothesis  that  elevated  plasma  total 
homocysteine  is  a  risk  factor  for  severe  coronary  atherosclerosis, 
independent of other risk factors for coronary artery disease. The relation 
was apparent over a wide range of total homocysteine levels. 
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Several  other  retrospective  case  control  studies  on  the  association  of 
plasma  total  homocysteine  with  angiographically  defined  coronary 
atherosclerosis  have  demonstrated  positive  associations,  with  fasting 
total homocysteine levels73, 74, 75, 76,77,78,79. This study is the first one done 
in  Palestine  with  this  number  of  cases  and  control  subjects  to 
demonstrate that fasting total plasma homocysteine levels are positively 
related  to  risk  of  coronary  atherosclerosis.  My  data  concur  with  a 
retrospective case control  study80  of coronary artery diseases  showing 
that frequency distribution of fasting total homocysteine were displaced 
to  the  right  relative  to  control  subjects.  A  clear  advantage  of  using 
angiographically defined coronary atherosclerosis as a disease end point 
is the possibility to grade the vascular disease. Others have shown that 
fasting total homocysteine increased with increasing number of occluded 
coronary arteries75,77.  In my study,  I  had the same observation,  which 
reinforces the hypothesis that elevated total homocysteine plays a role in 
the  atherosclerosis  process;  although  a  clear  cause-effect  relationship 
cannot be derived from this type of study. 
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The results of more than 75 clinical and epidemiological studies have 
indicated  a  positive  correlation  between  plasma  total  homocysteine 
levels  and  CAD,  peripheral  arterial  disease,  stroke  and  venous 
thrombus34, 81.
The results of these clinical studies are consistent  and agree with my 
findings that total plasma homocysteine has a strong positive association 
with coronary atherosclerosis.  Also, my finding that increased plasma 
total homocysteine is correlated with atherosclerosis.
A meta-analysis of 27 studies relating homocysteine levels to CAD and 
11  studies  of  the  effects  of  folic  acid  on  total  homocysteine  levels 
suggested  that  an increase  of  5  umol/L  in  the  level  of  homocysteine 
(normal level, 5-15 umol/L) 82 increased the risk for CAD as much as 
increase of 0.52 mmol/L (20 mg/dl) in the level of plasma cholesterol 
does3. The results of these meta-analysis studies agree with my finding 
that the estimated risk of atherosclerosis increases from 3.267(95% CI, 
2.1 – 5.0) to 8.21(95% CI, 4.1 – 10.86) for increase of homocysteine of 
1SD, using this study cutoff value which is 14.7±4.72 umol/L.
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With  few  exceptions83,  84,  most  other  retrospective  epidemiological 
studies of coronary heart disease showed a positive relation with plasma 
total  homocysteine85,86,87,88,89.  However,  data  from  prospective  studies 
offer  weaker  support  than  case  –control  studies  for  an  association 
between homocysteine concentration and cardiovascular disease. In the 
Physicians’  Health  Study,  with  a  5  year  follow  up,  plasma  total 
homocysteine levels above the 95th percentile of the control distribution 
were associated with a 3.4 fold increased risk of myocardial infarction5. 
However, the relative risk was 1.7 with 7.5 years of follow up, and this 
was  no  longer  statistically  significant.  Two  other  prospective  studies 
clearly  failed  to  show  an  association  whereas  another  showed  no 
association with incident coronary heart disease and an increased risk of 
coronary heart disease mortality only during the first 1.5 years of follow 
up5.   Two  other  studies  found  positive  associations,  but  these  were 
generally smaller than those observed in retrospective studies, especially 
when  subjects  with  preexisting  cardiovascular  disease  were  excluded 
from analyses.  Reasons for weaker associations in prospective studies 
may  include  deterioration  of  total  homocysteine  in  blood  samples  or 
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variations in subjects over time, leading to effect attenuation. Of course, 
another  possibility  may  be  that  elevated  total  homocysteine  is  not  a 
cause but merely a consequence of cardiovascular disease.
Also,  the accumulating  epidemiological  evidence linking high plasma 
levels of homocysteine to increased rates of heart disease is impressive. 
Researchers have postulated an even greater role for homocysteine than 
for cholesterol in atherogenesis75. This finding is also compatible with 
my  findings  that  homocysteine  is  stronger  as  a  risk  factor  for 
atherosclerosis  compared  to  cholesterol.  But,  still  research  is  yet  to 
definitively establish how an elevated level of homocysteine ranks as a 
marker for heart disease among the traditionally accepted risk factors. It 
appears reasonable to conclude that future outcome studies may release 
homocysteine from being a nontraditional risk factor for CAD to a wide 
acceptance as an independent risk factor for heart disease90,91.  
Although my data are compatible with a positive association between 
plasma total homocysteine and risk of coronary atherosclerosis, part of 
the  findings  did  not  reach  statistical  significance,  possibly  due  to 
relatively small numbers of subjects, especially when using cutoff points 
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for elevated total homocysteine. Like other studies, this study found that 
elevated  total  homocysteine  is  a  graded  risk  factor,  but  my  ORs  for 
increased plasma total homocysteine were higher. My ORs compared to 
the summary of the ORs mentioned in the latest meta-analysis82 were 
higher  also,  and  this  could  be  explained  that  this  is  the  case  in  our 
population, since there was no statistical difference between the cutoffs 
used in the study and my cutoff. So, to prove that, a large clinical trial 
should be done in Palestine on a large number of people to assess the 
exact relation between Hcy. and CAD, and to establish a more reliable 
cutoff value for Hcy.   
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Chapter 7
CONCLUSION
Conclusion:
In conclusion, my data suggest that elevated fasting total homocysteine 
is  an independent risk factor  for  severe  coronary atherosclerosis.  The 
association exists over a wide range of total homocysteine levels.
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Further studies are necessary to complement the growing evidence of the 
important role of elevated total homocysteine in cardiovascular disease 
etiology  and  to  further  elucidate  the  role  of  genetic,  nutritional,  and 
lifestyle factors. In my opinion, reduction of total homocysteine levels in 
the general population, and not only in those with clearly abnormal total 
homocysteine levels, may protect against cardiovascular disease.
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